This site is intended for US Healthcare Professionals only.

Dosing and usage

In accordance with its instructions for use,

Patients insert and press to administer neffy1

Preparing for administration of neffy:

  • Patients should be advised on when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required1
  • Each single-use neffy spray device delivers an intranasal dose containing 2 mg of epinephrine. Patients should not prime or attempt to reuse neffy for more than one administration1
  • It is recommended that patients are prescribed and have immediate access to 2 neffy devices at all times so that they are always prepared with a primary and a backup1
  • Single-use neffy can be administered while the patient is in any position (ie, supine, semi-supine, standing, or sitting)2
  • Remove neffy spray device from packaging before use3

During administration of neffy:

A graphic depiction of the administration of neffy® (epinephrine nasal spray): INSERT the nozzle into one nostril and PRESS the plunger to release the drug

To administer neffy, patients or caregivers should1:

HOLD the device with your thumb on the bottom of the plunger and a finger on either side of the nozzle

INSERT the nozzle of the nasal spray device fully into one nostril until their fingers touch the nose; they must not angle the nasal spray to the inside septum or outer wall of the nose as some medication may be lost

PRESS the plunger firmly to activate. Do not sniff during or after administration

Following administration of neffy:

  • In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of neffy may be administered in the same nostril with a second nasal spray starting 5 minutes after the first dose1
  • More than 2 sequential doses of epinephrine should be administered under direct medical supervision1

In studies designed to evaluate success of administration, 100% of adults and pediatric participants (N=16; N=42) were able to administer neffy without error4,5

neffy supply and storage considerations

A green-teal gradient circle with a blue box full of items in the center

Supplied in a carton with 2 devices in blister packs1

A green-teal gradient circle with a blue calendar that reads "24" on it in the center

Expiration date of 30 months after its manufacture date6

A green-teal gradient circle with a blue thermometer in the center

Store at 68°F to 77°F (20°C to 25°C). Excursions permitted up to 122°F (50°C)1*

*Do not freeze. neffy freezes below 5°F (-15°C). If neffy freezes, it will not deliver epinephrine.1

References: 1. neffy [prescribing information]. San Diego, CA: ARS Pharmaceuticals, Inc. 2. Data on file. ARS Pharmaceuticals Operations, Inc. 2024. 3. Instructions for use. ARS Pharmaceuticals Operations, Inc. 2024. 4. Data on file. Human Factors Study. ARS Pharmaceuticals Operations, Inc. 2024. 5. Data on file. EPI-17 CSR. ARS Pharmaceuticals Operations, Inc. 2022. 6. Data on file. neffy expiration date. ARS Pharmaceuticals Operations, Inc. 2024.

INDICATION AND IMPORTANT SAFETY INFORMATION

+

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 15 kg or greater.

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

neffy is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in neffy should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at. 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for neffy.